Developmental therapeutics for myelodysplastic syndromes

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 1, 2006, Pages 78-82

  Naing, Aung ^a,b   Sokol, Lubomir ^a,b   List, Alan F ^a,b,c  

^a College of Medicine ^*

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Hematologic Malignancy Program   (United States)

Author keywords

Clinical trial; Myelodysplastic syndrome; Targeted therapy

Indexed keywords

AMIFOSTINE; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; BEVACIZUMAB; CYCLOSPORIN; GLUTATHIONE DERIVATIVE; IMATINIB; LENALIDOMIDE; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; RECOMBINANT ERYTHROPOIETIN; SCIO 469; SEMAXANIB; SUGEN; SUNITINIB; TELINTRA; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; TLK 117; TLK 177; TLK 199; UNCLASSIFIED DRUG; VATALANIB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; GAMMA GLU S BZCYS PHGLY DIETHYL ESTER; GAMMA-GLU-S-BZCYS-PHGLY DIETHYL ESTER; GLUTATHIONE; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; SCIO-469;

CELL PROTECTION; CHROMOSOME 5Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CYTOGENETICS; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG MECHANISM; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FLUID RETENTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; GENETICS; IMMUNOLOGY;

AMIFOSTINE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; MYELODYSPLASTIC SYNDROMES;

EID: 33645070228     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0008     Document Type: Review

References (33)

1. Vardiman JW, Hariss NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:22292-22302.
2. Greenberg P, Cox C, Le Beau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
3. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:9671-9674.
4. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anemias without hypoplastic bone marrow. Br J Haematol 1998;100:304-309.
5. Molldrem JJ, Leifer E, Babeci E, et al. Antithymocyte globulin for treatment of bone marrow failure associated with myelodysplastic syndrome. Ann Intern Med 2002;137:156-163.
6. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699-705.
7. Barrett AJ, Molldrem JJ, Saunthrajarian Y, et al. Prolonged transfusion independence and disease stability in patients with myelodysplastic syndrome responding to antithymocyte globulin [abstract]. Blood 1998;92:713.
8. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003;102:3025-3027.
9. Gersuk GM, Lee JW, Beckham CA, et al. Fas (CD95) receptor and fas ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1998;88:1122-1123.
10. Stasi R, Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes [abstract]. Br J Haematol 2002;116:334.
11. Raza A, Qavi H, Lisak L, et al. Patients with myelodysplastic syndrome benefit from palliative therapy with amifostine, pentoxyfylline, and ciprofloxacin with or without dexamethasone. Blood 2000;95:580-587.
12. Grossi A, Musto P, Santini V, et al. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndrome. Haematologica 2002;87:322-323.
13. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-1434.
14. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-965.
15. Moreno-Aspitia A, Geyer S, Li C, et al. N998B: multicenter phase II trial of thalidomide (Thai) in adult patients with myelodysplastic syndromes (MDS) [abstract]. Blood 2002;100:96.
16. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557.
17. List A, Dewald G, Bennett J, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. J Clin Oncol 2005;23:28.
18. List AF, Schiller GJ, Mason J, et al. Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase II clinical study [abstract]. Blood 2003;102:423.
19. Raza A, Lisak LA, Tahir S, et al. Trilineage responses to arsenic trioxide (Trisenox®) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2) [abstract]. Blood 2002;100:795.
20. Vey N, Dreyfus F, Guerci A, et al. Trisenox (arsenic trioxide) in patients (pts) with myelodysplastic syndromes (MDS): preliminary results of a phase 1/2 study [abstract]. Presented at the 8th Congress of the European Hematology Association; June 12-15, 2003; Lyon, France.
21. Gotlib J, Jamieson C, List A, et al. Phase II study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS) [abstract]. Blood 2003;102:425.
22. Foran J, Paquette R, Copper M, et al. A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed or are not eligible for conventional chemotherapy [abstract]. Blood 2002;100:558.
23. Giles F, Steinfeldt H, Bellamy WT, et al. Phase 2 study of the antiangiogenesis agent AG-013736 in patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome [abstract]. Blood 2004;104:502.
24. Reuter CWM, Morgan MA, Bergmann L. Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96:1655-1669.
25. Golub T, Barker G, Lovett M, Gilliland D. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-316.
26. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
27. Nikas SN, Drosos AA. SFCIO-469 Scios Inc. Curr Opin Investig Drugs 2004;5:1205-1212.
28. Reuter CWM, Morgan MA, Bergmann L. Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies; Blood 2000;96:1655-1669.
29. Kurzrock R, Kantarjian HM, Cortes J, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003;102:4527-4534.
30. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004;22:1287-1292.
31. Feldman EJ, Cortes J, Holyoake T, et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome [abstract]. Blood 2003;102:421.
32. Buresh A, Perentesis J, Rimsza L, et al. Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia 2005;19:308-310.
33. Callander N, Ochoa-Bayona JL, Piro L, et al. Hematologic improvement following treatment with TLK199 (Telintra®), a novel glutathione analog inhibitor of GST P1-1, in myelodysplastic syndrome (MDS): interim results of a dose-ranging phase 2a study [abstract]. Blood 2004;104:1428.